Vitamin D deficiency in health care providers Vitamin D insufficiency in health care providers Vitamin D deficiency Vitamin D insufficiency Hypovitaminosis D
Conditions
Interventions
Vitamin D3 group received a 1,000 IU tablet of plain cholecalciferol (Vitamin D3) (NatD, Mega Life Sciences Limited (Thailand)) daily which is equivalent to 7000 IU of cholecalciferol per week for 12
Active Comparator Drug,Active Comparator Drug
Vitamin D3,Vitamin D2
Sponsors
Police Osteoporosis and Getriatric Excellence Center
Eligibility
Sex/Gender
Female
Age
25 Years to 65 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria were adult female aged 25 to 65 years without history of osteoporosis or fragility fractures as defined by fractures from a simple fall.
Exclusion criteria
Exclusion criteria: The exclusion criteria were prescription of vitamin D or calcium supplement within the past year, history of anti-osteoporotic medication use, including hormonal replacement therapy, and prescription of anticonvulsants or steroids. Underlying medical conditions that could affect bone metabolism; for example, hypocalcemia, hypercalcemia, uncontrolled hyperthyroidism, hypogonadism, primary hyperparathyroidism, growth hormone deficiency, acromegaly, hemochromatosis and chronic liver diseases, hematological disorders, renal disorders including chronic kidney disease, and autoimmune disorders, were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum 25-hydroxy vitamin D level (25(OH)D)) Baseline, 6 months, 12 months Chemiluminescent microparticle immunoassay (CMIA) on Architect I2000SR analyzer (Abbott Laboratories Limited, USA) | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance Baseline, 6 months, 12 months Medical possesstion ratio | — |
Countries
Thailand
Contacts
Public ContactTanawat Amphansap
Police General Hospital
Outcome results
None listed